Quandaries of responsible innovation: the case of Alzheimer's disease

Yvonne M. Cuijpers*, Harro van Lente, Ellen H.M. Moors, Marianne Boenink

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

6 Citations (Scopus)
1 Downloads (Pure)


The interest in responsible innovation has led to various activities to include social, economic and moral concerns in the process of innovation. This ambition, however, brings along several fundamental questions. We encountered these in a project on responsible innovation in the case of new molecular early diagnostics for Alzheimer’s disease (AD). Currently, a number of novel technologies are being developed for in vivo early diagnosis of AD, by identifying and testing new molecular biomarkers. In our project, we study scientific and clinical uncertainties in technology development, analyze the social and cultural as well as the moral implications of existing and alternative ways to deal with them. In this chapter we summarize the fundamental questions about responsible innovation in terms of six ‘quandaries’: problematic, difficult and ambiguous conditions that somehow require fundamental and practical decisions.
Original languageEnglish
Title of host publicationResponsible Innovation 1
Subtitle of host publicationInnovative Solutions for Global Issues
EditorsJeroen van den Hoven, Neelke Doorn, Tsjalling Swierstra, Bert-Jan Koops, Henny Romijn
Place of PublicationDordrecht
Number of pages16
ISBN (Electronic)978-94-017-8956-1
ISBN (Print)978-94-017-8955-4
Publication statusPublished - 2014


  • Innovation process
  • Health technology assessment (HTA)
  • Informal caregivers
  • Technology developer
  • Responsible innovation


Dive into the research topics of 'Quandaries of responsible innovation: the case of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this